Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Concepta addresses supply chain issues after order delay of myLotus fertility product

Orders increased in the last few months of 2017 and the group expects further new distributors to be appointed in the new year
The company's key product is myLotus, a women's fertility home test

UK healthcare firm Concepta PLC (LON:CPT) said it is taking action to improve its supply chain after issues with a manufacturer resulted in a delay to a significant order.

A labelling quality issue with the company's manufacturer in China meant it did not receive sufficient monitors to meet an order for myLotus fertility metres by the ShanDong WeiHai HaiChen Pharmaceutical Co.

READ: Concepta says myLotus fertility product got an “excellent reception” at meeting of potential distributors in China

The £600,000 Chinese order will now be delivered in January, meaning revenues from the deal will be recognised in the first quarter of 2018 instead of by the end of 2017 as announced in November.

However, chief executive Erik Henau said the company has had a team on the ground over recent months to tackle the issues in its supply chain as it ramps up production.

“The China team will have the support of David Darrock as chief operating officer who has experience in the move from assembling products in a laboratory environment to full scale commercial manufacturing,” he said.

“We enforce strict quality control standards on our products and as such we have commenced a full supply chain evaluation with our suppliers and have implemented a number of measures to strengthen processes, for which we are already seeing significant improvements.

READ: Concepta raises £2mln to fund China expansion

“Despite the impact of these issues I am confident that, following the improvements made, we are entering 2018 in a much stronger position."

In the last few months of 2017 orders have increased and the group expects further new distributors to be appointed in the new year.

Following a recent £2mln fundraise, the company also has sufficient cash to meet its working capital requirements through 2018.

View full CPT profile View Profile

Concepta Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use